CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells.
about
Adoptive T-Cell ImmunotherapyAdoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized miceProgrammed Death-1 expression on Epstein Barr virus specific CD8+ T cells varies by stage of infection, epitope specificity, and T-cell receptor usageEpstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapyImmunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapyThe Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradationThe CD8 and CD4 T-cell response against Kaposi's sarcoma-associated herpesvirus is skewed towards early and late lytic antigens.Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome.Altered CD8(+) T cell immunodominance after vaccinia virus infection and the naive repertoire in inbred and F(1) mice.Rapid recruitment of virus-specific CD8 T cells restructures immunodominance during protective secondary responsesThe EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and eliminationVirus and cell RNAs expressed during Epstein-Barr virus replicationA panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.T cell epitope clustering in the highly immunogenic BZLF1 antigen of Epstein-Barr virus.The cycle of EBV infection explains persistence, the sizes of the infected cell populations and which come under CTL regulation.Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.Persistent infection drives the development of CD8+ T cells specific for late lytic infection antigens in lymphocryptovirus-infected macaques and Epstein-Barr virus-infected humans.Inhibition of heavy chain and beta2-microglobulin synthesis as a mechanism of major histocompatibility complex class I downregulation during Epstein-Barr virus replicationLatent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells.Lytic and latent antigens of the human gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus induce T-cell responses with similar functional properties and memory phenotypesEarly T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination.Portable flanking sequences modulate CTL epitope processing.A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates.The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation.Professional antigen presenting cells in human herpesvirus 8 infection.EBV BILF1 evolved to downregulate cell surface display of a wide range of HLA class I molecules through their cytoplasmic tail.Dissociation between epitope hierarchy and immunoprevalence in CD8 responses to vaccinia virus western reserve.An HLA-A2-restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP.Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis.The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosisImmune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunityFactors influencing immunodominance hierarchies in TCD8+ -mediated antiviral responses.Prospects of a novel vaccination strategy for human gamma-herpesviruses.Understanding human T-cell-mediated immunoregulation through herpesviruses.Epstein-Barr virus genetics: talking about the BAC generation.Ovarian cancer molecular pathology.The pathogenesis of Epstein-Barr virus persistent infection.The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-IIThe viral transcription group determines the HLA class I cellular immune response against human respiratory syncytial virus.
P2860
Q26782845-246E706C-479D-404A-AFEA-33D34060D9CAQ27324235-2815D425-342B-49E0-BE77-76B1A79F015AQ28749172-28FE89BD-0FC2-419D-B325-B4E44E792C72Q30878158-78221D1F-995D-48E0-8FA0-7B2E675D09F7Q33289956-0197E37B-D616-4169-B4F0-38710839DE20Q33396983-A27C7D4D-AB5C-47E6-888C-28682B11555CQ33470219-4A4F3D80-E37F-4198-AAC5-A64CCF0F3C41Q33474804-A75BB436-FAA7-4823-967F-8836BBB7B996Q33640163-C84B4434-31B3-4DF0-B791-664D623A8A44Q33754153-CCA85C4B-79F7-40C5-936B-723B1378D975Q34045631-59AFAF2E-09F1-48E0-85B6-435142AAB1C7Q34277034-9F80F0FE-5FC6-4127-84FC-A62808D21CC7Q34434702-DBAAF33B-D307-4451-B916-86B694D99592Q34815702-A2271884-865E-43B2-818E-CD229B73B729Q34992684-596A7453-3932-4E96-AD78-70AC52169F98Q35022301-C6772C59-6BF5-4ADF-92E3-889A9A3E8BABQ35222179-FDA43F45-AEC2-4D88-8826-9D4BF604B0CBQ35531669-6DD71E2B-05E3-4146-8594-29CD695E158CQ35635291-7E3E5DA0-2600-4014-9847-BE447DF5634EQ35661383-EADC1E9D-40D5-4333-B431-6EF2494A6820Q35857401-C4003124-B6B8-4107-ABA0-8EDC27C7646AQ35994831-72C60767-53D8-4AFA-96A4-565B8CE3F7B4Q36099407-E02DE806-0EC1-411C-82CF-53F6BAD8E447Q36229606-D2172EA7-E2B8-4481-8D77-22290E80CAB2Q36403686-7B16F590-70B6-4038-8BB8-B2DDCCAE919EQ36546999-CB222722-40E7-4AF6-85D5-A65761AEE516Q36590231-5C789442-9A4B-4DCB-B32E-B61B7D2A3262Q36871818-2414B3B3-E203-4149-A99F-B4AC2BCC5B5FQ37110627-1C7C4E68-397A-439C-BA5A-246527360B41Q37145510-B7D227F9-4338-4F9F-A884-20237216DC24Q37151141-76A3E87D-AC77-49C8-B10E-EA2289BEB8BBQ37652046-70D8017F-1795-407D-8787-018B655B5082Q37754754-B86FAE64-C77E-4CC6-856E-F70076F95D7EQ37780705-B1522460-A26E-41CB-B035-030AFFF65E0BQ37837487-29165676-4D2A-4953-9BAC-C4849A96D5D3Q37856451-C897187C-7255-49A3-BF35-E2919A0A0CE6Q38021356-7F792237-EA98-497E-94AF-B602F4BB4F89Q38107595-21802B98-B3FB-4FE0-977F-D13FF68DDB44Q38827812-3E2908B2-34C8-4FFC-AE8A-0DC18FB9A0EFQ38915023-815AB847-5AD1-4D26-8523-23867B588A08
P2860
CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
CD8+ immunodominance among Eps ...... n in lytically infected cells.
@en
CD8+ immunodominance among Eps ...... n in lytically infected cells.
@nl
type
label
CD8+ immunodominance among Eps ...... n in lytically infected cells.
@en
CD8+ immunodominance among Eps ...... n in lytically infected cells.
@nl
prefLabel
CD8+ immunodominance among Eps ...... n in lytically infected cells.
@en
CD8+ immunodominance among Eps ...... n in lytically infected cells.
@nl
P2093
P2860
P356
P1476
CD8+ immunodominance among Eps ...... n in lytically infected cells.
@en
P2093
Alan B Rickinson
Alison M Leese
Andrew D Hislop
Victoria A Pudney
P2860
P304
P356
10.1084/JEM.20041542
P407
P577
2005-01-31T00:00:00Z